CoChat

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Oral anti-diabetic agents have been associated with adverse cardiovascular events in type 2 diabetes (DM2). We investigated the risk of coronary artery disease (CAD), congestive heart failure (CHF), and mortality using multivariable Cox models in a retrospective cohort of 20,450 DM2 patients from our electronic health record (EHR). We observed no differences in CAD risk among the agents. Metformin was associated with a reduced risk of CHF (HR 0.76, 95% CI 0.64-0.91) and mortality (HR 0.54, 95% CI 0.46-0.64) when compared to sulfonylurea. Pioglitazone was also associated with a lower risk of mortality when compared to sulfonylurea (HR 0.59, 95% CI 0.43-0.81). No other significant differences were found between the oral agents. In conclusions, our results did not identify an increased CAD risk with rosiglitazone in clinical practice. However, the results do reinforce a possible increased risk of adverse events in DM2 patients prescribed sulfonylureas.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00592-008-0090-3

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 126

Metadata

Authors
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S.
Affiliations
Cleveland Clinic (US)
Corresponding author
Pantalone, Kevin M.
Venue
Acta Diabetologica
Published
2009-02-05
Volume
46
Issue
2
Pages
145-154
ISSN
  • 0940-5429 (ISSN-L)
  • 1432-5233
OpenAlex
W2020353068
Cited by
123
References
25
Citations by year
2026: 2 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 8 · 2020: 11 · 2019: 11 · 2018: 9 · 2017: 12 · 2016: 10 · 2015: 10 · 2014: 3 · 2013: 5 · 2012: 8
FWCI
7.99
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Acta Diabetologica (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords
type 2 diabetes, rosiglitazone, pioglitazone, metformin, sulfonylureas, coronary artery disease, congestive heart failure, all-cause mortality, cardiovascular adverse events, oral antidiabetic drugs, drug safety
MeSH terms
Rosiglitazone, Angiotensin-Converting Enzyme Inhibitors, Coronary Artery Bypass, Coronary Disease, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Heart Failure, Humans, Hypoglycemic Agents, Male, Metformin, Retrospective Studies, Risk Factors, Smoking, Sulfonylurea Compounds, Multivariate Analysis, Proportional Hazards Models, Survival Analysis, Survivors, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. https://app.cochat.ai/papers/10.1007/s00592-008-0090-3
The paper
Pantalone, K. M., Kattan, M. W., Yu, C., Wells, B. J., Arrigain, S., Jain, A., Atreja, A., & Zimmerman, R. S. (2009). The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetologica. https://doi.org/10.1007/s00592-008-0090-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.